TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07700979: Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously

Sponsor: Akeso · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 900 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07700979 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07700979 Rescue Dossier →